-+ 0.00%
-+ 0.00%
-+ 0.00%

NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model

Barchart·08/14/2026 07:59:00
Listen to the news

TORONTO and HAIFA, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based regenerative therapies, today announced new preclinical tissue-analysis results that provide additional biological support for ExoPTEN’s potential neuroprotective effect in an animal model of traumatic spinal cord injury.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.